CalciMedica, Inc. Stock Price

NasdaqCM:CALC Community·US$42.8m Market Cap

0 Narratives written by author
0 Comments on narratives written by author
2 Fair Values set on narratives written by author

Create a narrative

CALC Share Price Performance

US$3.04

-0.46 (-13.14%)

US$3.04

-0.46 (-13.14%)

US$3.04

Sun, 9 Nov 25

Share PriceUS$3.04

CALC Community Narratives

There are no narratives available yet.

Create a narrative

There are no community narratives available.

Snowflake Analysis

Moderate risk with mediocre balance sheet.

5 Risks

1 Reward

View Full Analysis

CalciMedica, Inc. Key Details

Last Reported Earnings

Jun 30, 2025

Next Reporting Earnings

n/a

: -1.49
: 0%
: 0%
: 139.3%

View Full Analysis

About CALC

Founded: n/a
Employees: 15
CEO: A. Leheny
WebsiteView website: calcimedica.com

CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company’s lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops Auxora for the treatment of acute ulcerative colitis, traumatic brain injury, and allergic asthma; and oral CRAC channel inhibitors for use in chronic inflammatory indications. The company is based in La Jolla, California.